Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention APOE4 gene, the most common co-covered peer. The tracked stories average 2 original sources each. JAMA appears in 1 tracked Biotech story from July 25, 2026.
Last mentioned: Jul 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention APOE4 gene, the most common co-covered peer. The tracked stories average 2 original sources each. JAMA appears in 1 tracked Biotech story from July 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 15 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering JAMA. Shared-story counts are live from our verified record — not editorial picks.
The p-tau217 blood test’s ability to identify cognitively healthy adults with up to 78% ten-year risk of cognitive decline offers pharma a powerful tool to enrich Alzheimer prevention trials, potentially accelerating drug development and reducing costs.
Source: medicalnewstoday.com · irishdentist.ie
JAMA is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
